Item is in stockHurry! Low InventoryItem is out of stock. Item is unavailable
Need to speak with a clinician?

Schedule a telehealth consultation with a practitioner specialized in peptide therapy, who will review your medical history and determine the best plan for you.

Proper Handling

Product Specifications: 10mg / 30mg Lyophilized Powder (>98% purity) in 4ml vial.*Requires reconstitution with solvent such as Bacteriostatic Water. Speak to a qualified healthcare professional if you are considering peptide therapy.

Promotes Fat Loss
Manages Appetite
Fights Type 2 Diabetes
Prevents Cognitive Decline
Lowers Blood Pressure

Tirzepatide is the active pharmaceutical ingredient used in Mounjaro® and Zepbound™*. Tirzepatide is a unique dual RA of both the GLP-1 and GIP receptors, which significantly reduces HbA1c levels and body weight in patients with T2DM and obesity. Its once-weekly dosing and potential cardiovascular benefits make Tirzepatide an attractive option for treating these conditions.

Tirzepatide is different from Semaglutide, because it also mimics the GIP hormone, so it not only affects stomach emptying and appetite, but also affects how fat is deposited in the body.

Tirzepatide is a novel medication that is FDA approved for the treatment of type 2 diabetes mellitus. The FDA approved Tirzepatide for chronic weight management in adults with obesity or overweight plus one weight-related comorbidity.

CAS Number 2023788-19-2

PubChem CID 2023788-19-2

Molecular Weight 4813.527 g/mol

Molecular Formula C225H348N48O68

Synonyms Mounjaro®, Zepbound™, GTPL11429, P1206, LY3298176

Storage (Lyophilized)

At 39 Fahrenheit: 2 years
At -4 Fahrenheit: 3 years

  1. Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide is a glucagon like peptide-1 receptor agonist with cardiovascular benefits for the management of type 2 diabetes. Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. doi: 10.1007/s11154-021-09699-1. Epub 2022 Jan 7. PMID: 34993760; PMCID: PMC8736331. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8736331/
  2. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155. doi: 10.3389/fendo.2019.00155. PMID: 31031702; PMCID: PMC6474072. https://pubmed.ncbi.nlm.nih.gov/31031702/
  3. Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018 Feb;41(2):258-266. doi: 10.2337/dc17-0417. Epub 2017 Dec 15. PMID: 29246950. https://pubmed.ncbi.nlm.nih.gov/29246950/
  4. Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb 15. PMID: 30768766. https://pubmed.ncbi.nlm.nih.gov/30768766/
  5. National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 56843331, Semaglutide.
  6. Yang Z, Chen M, Carter JD, Nunemaker CS, Garmey JC, Kimble SD, Nadler JL. Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem Biophys Res Commun. 2006 Jun 9;344(3):1017-22. doi: 10.1016/j.bbrc.2006.03.177. Epub 2006 Apr 5. PMID: 16643856. https://pubmed.ncbi.nlm.nih.gov/16643856/</>
  7. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006 Jul;8(4):436-47. doi: 10.1111/j.1463-1326.2006.00602.x. PMID: 16776751. https://pubmed.ncbi.nlm.nih.gov/16776751/
  8. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. The glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003 Sep;9(9):1173-9. doi: 10.1038/nm919. Epub 2003 Aug 17. PMID: 12925848. https://pubmed.ncbi.nlm.nih.gov/12925848/
  9. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology. 2003 Jun;144(6):2242-52. doi: 10.1210/en.2003-0007. PMID: 12746281. https://pubmed.ncbi.nlm.nih.gov/12746281/

Buy It With

BPC-157 / TB-500 Blend


 TB-500 Blend

Buy It With

Bacteriostatic Water


Bacteriostatic Water

Frequently Asked Questions


Free Shipping

on all orders over $200 delivered straight to your doorstep

Easy Telehealth

Ongoing care available, 100% online at your convenience

Quality First

All peptides are clinical grade and undergoes third-party testing

Proactive Care

Your journey, your way. We are here to support your health goals.


Your body, your journey .

Embarking on the journey to better health involves embracing holistic well-being through consultative care. It's not just about staying clear of sickness; it's about finding balance in body and mind.